Small Cell Lung Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial.
SIGNAL TRANSDUCT TAR · Q1 JOURNAL - RANK #1/319TOP-TIER
This randomized phase II trial evaluated induction camrelizumab plus etoposide-platinum chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation versus induction chemotherapy plus concurrent chemoradiotherapy alone in 41 previously untreated limited-stage small cell lung cancer patients. The primary endpoint was 1-year progression-free survival rate; secondary endpoints included objective response rate, PFS, overall survival, and safety. At median follow-up of 32.1 months, the camrelizumab group demonstrated significantly higher 1-year PFS (65.5% vs 47.4%, P=0.029), longer median PFS (24.0 vs 11.8 months), and improved median OS (not reached vs 23.9 months, P=0.042), with manageable toxicities including 4.8% severe immune-related adverse events. The authors conclude that this induction-consolidation camrelizumab strategy significantly improved survival outcomes with a manageable safety profile, warranting further validation.
10.1038/s41392-026-02984-y
Sep 28 – Oct 05, 2026
Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A).
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This phase II randomized controlled trial evaluated toripalimab consolidation versus observation in 98 patients with limited-stage small cell lung cancer who had completed concurrent chemoradiotherapy. Patients were randomized 1:1 to toripalimab 240 mg every 3 weeks for up to 6 months or observation, with progression-free survival as the primary endpoint. Median PFS was not reached with toripalimab versus 14.1 months with observation (HR 0.55, 95% CI 0.31-0.96), and median OS was not reached versus 30.3 months (HR 0.39, 95% CI 0.19-0.80). The authors concluded that consolidative toripalimab showed promising PFS and OS signals with manageable safety, warranting confirmation in larger trials.
10.1136/jitc-2026-016467
Sep 21 – Sep 28, 2026
AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This phase I/Ib dose-expansion trial evaluated ociperlimab plus tislelizumab with or without chemotherapy in patients with metastatic NSCLC or ES-SCLC. The study enrolled 198 patients across five cohorts: untreated sqNSCLC (n=41), untreated non-sqNSCLC (n=43), untreated PD-L1+ NSCLC (n=45), checkpoint inhibitor-experienced NSCLC (n=26), and untreated ES-SCLC (n=43). Objective response rates ranged from 7.7% to 65.9%, with median progression-free survival between 2.9 and 11.3 months, while treatment-related Grade 3-4 adverse events occurred in 20.0% to 60.5% of patients. The combination demonstrated manageable safety and preliminary antitumor activity, though findings from this small phase I study should be interpreted with caution.
10.1136/jitc-2026-015474
First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study.
LUNG CANCER · Q1 JOURNAL - RANK #19/108
This single-arm phase II trial evaluated first-line camrelizumab plus platinum-etoposide chemotherapy followed by camrelizumab-apatinib maintenance in 41 treatment-naïve patients with extensive-stage small-cell lung cancer (ES-SCLC). The primary endpoint was 6-month progression-free survival (PFS) rate, with secondary endpoints including objective response rate (ORR), disease control rate (DCR), overall survival (OS), PFS, and safety. At a median follow-up of 31.0 months, the 6-month PFS rate was 71.1%, with median PFS and OS of 8.7 and 17.2 months, respectively; ORR was 82.9% and DCR was 92.7%. Grade ≥3 treatment-related adverse events occurred in 22.0% of patients, and exploratory analyses suggested a ‘high-CD8/low-M2’ immune phenotype and a 9-gene expression pattern associated with benefit.
10.1016/j.lungcan.2026.109623
Sep 14 – Sep 21, 2026
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 3, multicenter, open-label, randomized trial evaluated tambotatug pelitecan versus topotecan in 451 patients with relapsed extensive-stage small-cell lung cancer after platinum-based therapy. The primary end point was overall survival, with key secondary end points of progression-free survival and objective response. Median overall survival was 13.3 months with tambotatug pelitecan versus 9.4 months with topotecan (HR 0.46, 95% CI 0.35-0.62, P<0.001), and median progression-free survival was 7.4 versus 2.8 months (HR 0.29, 95% CI 0.23-0.37, P<0.001). Confirmed objective response rates were 59.1% versus 9.7% (P<0.001), with lower grade 3+ adverse events (55.4% vs 77.9%), leading to the conclusion that tambotatug pelitecan significantly improves survival outcomes in this population.
10.1056/NEJMoa2610229
Aug 31 – Sep 07, 2026
Neoadjuvant PD-1 Blockade Tislelizumab (BGB-A317) in Combination With Etoposide and Platinum-Based Chemotherapy for Limited-Disease Small Cell Lung Cancer.
MEDCOMM · Q1 JOURNAL - RANK #14/195TOP-TIER
This prospective Phase II trial evaluated neoadjuvant tislelizumab combined with etoposide and platinum chemotherapy in 15 patients with limited-disease small cell lung cancer (LD-SCLC), assessing tumor response, surgical outcomes, and survival. The objective response rate was 66.7%, and 60% of patients underwent curative-intent surgery with all achieving R0 resection; among surgical cases, major pathological response and pathological complete response were 44.4% and 33.3%, respectively. Median event-free survival was 21.7 months and overall survival was 32.7 months, with PET-CT metabolic response better predicting pathological remission than radiographic shrinkage. The study concludes that this neoadjuvant immunochemotherapy is feasible and shows promising efficacy, while transcriptomic analyses reveal potential resistance mechanisms, suggesting avenues for refinement.
10.1002/mco2.70972
Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes.
LUNG CANCER · Q1 JOURNAL - RANK #19/108
This study analyzed baseline tumor samples from a subset (n=77) of a randomized trial (n=170) that compared high-dose (60 Gy) versus standard-dose (45 Gy) twice-daily thoracic radiotherapy with concurrent chemotherapy in limited-stage small cell lung cancer (SCLC), aiming to identify molecular subtypes and correlate them with outcomes. Non-negative matrix factorization defined subtypes in 81 samples, identifying inflamed subtypes (SCLC-I-NE, SCLC-I-nNE) and SCLC-N (NEUROD1-driven). Univariable analysis showed SCLC-I-NE was associated with longer time to progression (HR 0.10, 95% CI 0.01-0.80), and SCLC-I-nNE with improved overall survival (HR 0.16, 95% CI 0.03-0.77), while SCLC-N was linked to worse TTP (HR 6.90) and OS (HR 4.89). The authors conclude that inflamed subtypes predict improved outcomes while SCLC-N predicts unfavorable outcomes in this patient group.
10.1016/j.lungcan.2026.109606
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
LUNG CANCER · Q1 JOURNAL - RANK #19/108
This prespecified analysis of the multicenter, open-label, randomized phase 3 DeLLphi-304 trial evaluated patient-reported outcomes (PROs) in 509 adults with extensive-stage small cell lung cancer (ES-SCLC) receiving tarlatamab versus standard-of-care (SoC) chemotherapy after first-line platinum-based therapy. Validated instruments including EORTC QLQ-C30, QLQ-LC13, FACT-G GP5, BPI-SF, and EQ-5D-5L were used, with compliance above 69% through 19 weeks. A higher proportion of tarlatamab-treated patients showed improvement at 19 weeks versus SoC in chest pain (19% vs 10%), cough (35% vs 26%), dyspnea (22% vs 7%), physical functioning (13% vs 8%), and global health status (23% vs 15%); tarlatamab also delayed deterioration in symptoms and pain. The authors concluded that tarlatamab demonstrated clinically meaningful PRO improvements and a favorable benefit-risk profile versus SoC.
10.1016/j.lungcan.2026.109581
Aug 24 – Aug 31, 2026
Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209).
FRONT IMMUNOL · Q1 JOURNAL - RANK #32/183
This open-label, single-arm, multicenter phase 2 trial evaluated the safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) combined with carboplatin and etoposide (EC) in 40 patients with extensive-stage small cell lung cancer (ES-SCLC). Treatment comprised QL1706 plus EC every 3 weeks for 4-6 cycles followed by QL1706 maintenance. The primary endpoint was safety, with all patients experiencing at least one treatment-related adverse event (TRAE), primarily hematologic; grade 3 immune-related adverse events occurred in 5.0% of patients, with no TRAE-related deaths or discontinuations. Among 38 efficacy-evaluable patients, the confirmed objective response rate was 92.1% (95% CI 78.6-98.3), median progression-free survival was 6.0 months (95% CI 5.4-8.3), and median overall survival was 15.8 months (95% CI 11.4-20.0), concluding that the regimen was well-tolerated with promising antitumor activity warranting phase 3 validation.
10.3389/fimmu.2026.1879524